Small molecule inhibitors of BRAF in clinical trials.
Over the last few years, BRAF has emerged as a validated target in melanoma. This review summarises recent advances in the development of BRAF inhibitors, focussing on agents that have been assessed clinically.
The Institute of Cancer Research, Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom.
Alfonso
A
Zambon
Ion
I
Niculescu-Duvaz
Dan
D
Niculescu-Duvaz
Richard
R
Marais
Caroline J
CJ
Springer
D002986:Clinical Trials as Topic; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000378:metabolism; D008970:Molecular Weight; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D013329:Structure-Activity Relationship
D047428:Protein Kinase Inhibitors; D048493:Proto-Oncogene Proteins B-raf